Table 1 An overview of treatment outcome in Pakistani HBV treated patients
Author | Region | Patients (n) | Etiology | Treatment | Duration (weeks) | Results |
|---|---|---|---|---|---|---|
Qureshi et al:[19] | Karachi | 69 | HBeAg, HBV DNA positive patients | 100 mg of Lamivudine orally before breakfast till seroconversion | 36 months | 38% cases were observed to sero-converted. |
Qureshi et al: [19] | Karachi | 55 | HBV DNA positive (wild type) with delta positive | 100 mg of Lamivudine orally before breakfast till seroconversion | 36 months | 16.4% cases in group 2 sero-converted (Wild type of HBV/HDV co-infected cases have a 16% chance of seroconversion) |
Naeem et al:[31] | Rawalpindi | 50 | Chronic viral hepatitis B (HBsAg and HBV DNA positive) | 5 mega units of recombinant interferon alfa-2b subcutaneously once daily | 4-months | HBV DNA was found negative in 44.0% (22) patients while treatment was ceased in three patients due to severe depression. |
Zuberi et al: [21] | Karachi | 246 | co/super-infection of Hepatitis C and D among patients of HBV | pegylated interferon-a 2a 180 mcg sc weekly | 48 weeks | HBV was not cleared in any case |
Zuberi et al: [32] | Karachi | 52 | patients of hepatitis B with hepatitis D | Interferon - a 10.0 MIU sc t.i.w. | 48 weeks | 51.9% patients had suppressed (< 400 copies/ml) HBV DNA levels |
Khokhar et al. [21] | Islamabad | 105 | positive HBsAg and elevated ALT | lamivudine 100 mg once a day for 12 months | 12 months and were followed every 2-3 months with ALT, HBeAg and HBV DNA | HBeAg positive and HBeAg negative patients were found with 23.6% and 80.0% treatment response rate respectively (All the patients were HBsAg positive) |